

Oxytocin and vasopressin levels are decreased in the plasma of male schizophrenia patients

Jobst A. Dehning S. Ruf S. Notz T. Buchheim A. Henning-Fast K. Meißner D. Meyer S. Bondy B. Müller N. Zill P. Oxytocin and vasopressin levels are decreased in the plasma of male schizophrenia patients.

Objective: Impaired social functioning and autistic symptoms are characteristics of schizophrenia. The social hormones oxytocin (OT) and arginine-vasopressin (AVP) both modulate social interaction and therefore may be involved in the pathogenesis of schizophrenia. We investigated whether men with schizophrenia show altered OT and AVP levels compared with healthy controls (HC) and whether autism symptoms are associated with OT levels.

Methods: Forty-one men with non-acute schizophrenia and 45 matched HC were enrolled. Schizophrenia was assessed with the Positive and Negative Syndrome Scale (PANSS). Blood samples were collected on 2 days, and plasma OT and AVP levels were measured by ELISA immunoassay.

Results: The schizophrenia patients had significantly lower plasma OT levels than the HC; a similar trend was found for AVP. Plasma OT levels were associated with severe life events, fewer important attached persons, and a higher score on the PANSS negative scale; the most dominant PANSS items were 'preoccupation', 'emotional withdrawal', and 'passive/apathetic social withdrawal'.

Conclusion: These findings support an association between the social hormones OT and AVP and schizophrenia. We suggest that OT metabolism may be altered in schizophrenia, but other possible causes for decreased plasma OT levels in schizophrenia patients include decreased OT synthesis, mRNA expression, and translation. Especially the 'autistic' symptoms of schizophrenia seem to be closely linked to an altered metabolism of OT, the 'attachment' hormone.

Andrea Jobst¹, Sandra Dehning¹, Simone Ruf¹, Tobias Notz¹, Anna Buchheim², Kristina Henning-Fast¹, Dominik Meißner¹, Sebastian Meyer¹, Brigitta Bondy¹, Norbert Müller¹, Peter Zill¹

¹Department of Psychiatry and Psychotherapy, Ludwig Maximilian University, Munich, Germany; and ²Department of Psychology, Clinical Psychology, University of Innsbruck, Innsbruck, Austria

Keywords: attachment; oxytocin; schizophrenia; social deficits; vasopressin

The authors A.J. and S.D. contributed equally to this paper

Andrea Jobst, Department of Psychiatry and Psychotherapy, Ludwig Maximilian University, Nussbaumstrasse 7, 80336 Munich, Germany.
 Tel: +49 89 44005 5331;
 Fax: +49 89 44005 4548;
 E-mail: A.Jobst@med.uni-muenchen.de

Accepted for publication June 28, 2014

First published online October 7, 2014

Significant outcomes

1. Lower plasma oxytocin (OT) and arginine-vasopressin (AVP) levels in schizophrenia patients than in healthy controls (HC);
2. OT plasma levels associated with severe life events and fewer important attached persons; and
3. OT plasma levels associated with negative symptoms of schizophrenia.

Limitations

1. Intake of atypical antipsychotic drugs might have affected OT and AVP plasma levels.
2. Results might be gender related and cannot be transferred to female patients; and
3. OT levels in plasma should be compared with levels in cerebrospinal fluid.

Introduction

In 1908, Eugen Bleuler, who coined the term 'schizophrenia', described autistic symptoms as so-called core symptoms of schizophrenia (1).

Today, the core symptoms of schizophrenia are considered to include positive and negative symptoms and cognitive impairment, and the autistic symptoms of schizophrenia are indicated rather by the following items on the Positive and Negative Syndrome Scale

(PANSS) (2): poor attention, preoccupation, difficulty in abstract thinking, stereotyped thinking, disturbance of volition, and hallucinations (3). Schizophrenia often begins with prodromal symptoms such as preoccupation and isolation. Impaired social functioning (4), emotional deficits (5), and a reduced Theory of Mind (6) then later characterise schizophrenia patients over the course of the disease. It is important to gain an understanding of impaired social functioning in schizophrenia and the underlying neurobiological mechanisms, because social outcomes are more strongly affected in schizophrenia patients than vocational or residential outcomes, and because real-world social outcomes are mostly predicted by blunted affect and passive-apathetic social withdrawal (7).

The closely related neuropeptides and social hormones OT and AVP both modulate social interactions in humans (8) and therefore are attractive candidates for involvement in the pathogenesis of schizophrenia. OT is known to facilitate 'trust' behaviour (9) and the ability to detect subtle emotional cues from pictures of eyes (10), whereas AVP seems rather to be associated with male-typical social behaviours such as reproduction, aggression, and territoriality (8,11). OT and AVP are synthesised in magnocellular neurons in the paraventricular and supraoptic nuclei of the hypothalamus and are processed along the axonal projections to the posterior lobe of the pituitary, where they are stored in secretory vesicles and released into the peripheral circulation. In addition, OT and AVP are released from dendrites into the extracellular space, resulting not only in local action but also in diffusion through the brain to reach distant targets in the periphery (12).

Several studies suggest the hypothesis that alterations in the OT and AVP system contribute to the social deficits and disabling cognitive and motivational impairment in patients with schizophrenia and that administration of OT and AVP may have clinical benefits. However, results are still inconclusive: Regarding the OT system, some studies initially reported elevated plasma OT-neurophysin or cerebrospinal fluid (CSF) OT levels in schizophrenia patients compared with HC (13,14), whereas other authors found no alteration in CSF levels in schizophrenia patients compared to HC (15,16). Goldman et al. (17) found decreased plasma OT only in schizophrenic patients with polydipsia and hyponatremia: Blunted plasma OT levels in schizophrenic patients were associated with a low performance in a facial affect rating task. In another study, endogenous reactivity of the OT system within a trust-related interpersonal interaction did not show differences between schizophrenic patients and HC, but decreased trust-related endogenous release of OT was associated with negative symptoms in the patient

group (18). Other recent studies gave further evidence for an association between OT levels and clinical symptoms in schizophrenia. OT blood levels were inversely correlated with symptom severity in women with schizophrenia (19), but not in men; pro-social behaviour and higher OT levels were correlated in both sexes (19). In a very recent study, Rubins et al. (20) found a correlation between higher plasma OT levels and greater positive symptom severity. However, within another previous sample Rubins found no significant difference in plasma OT between acutely ill, unmedicated first-episode schizophrenia patients and HC and no association with clinical symptoms and cognition (21). Another study found a negative correlation between CSF OT and the negative PANSS subscale in male patients with schizophrenia (16). Therefore, schizophrenia patients might benefit from OT treatment, and the question of a therapeutic use is gaining increasing interest. Antipsychotic-like effects have been attributed to endogenous OT or systemically administered OT in several different animal models relevant to schizophrenia (22–24), and two older clinical trials already demonstrated therapeutic effects of OT administration in patients with schizophrenia (25,26). Recent studies replicated these results: The adjunctive application of intranasal OT in 15 schizophrenia patients significantly reduced PANSS scores, the greatest reduction being in negative symptoms (27). Moreover, Feifel et al. (28) reported positive effects of OT administration on cognition in schizophrenia patients. Modabbernia found that PANSS positive, negative, and global symptoms improved after OT administration (29), and Pedersen et al. (30) found that psychotic symptoms decreased and social cognition improved after OT administration. A single intranasal application of OT improved performance in a higher-level social cognition task in schizophrenia patients (31). Another study showed that the hormone improved fear recognition among schizophrenia patients and HC whose baseline performance was below the median; this improvement was regardless of the individuals' psychiatric status, and OT did not differentially affect emotion recognition in patients and HC in this cohort (32). A recent study explored whether 10 or 20 IU of intranasal OT reverses the impaired discrimination of facial affect in schizophrenia patients and found improved emotion recognition after 20 IU OT in polydipsic relative to non-polydipsic patients but worse emotion recognition after 10 IU in both patient groups (33).

Several authors have found evidence of AVP alterations in schizophrenia patients, although first studies could not find differences in CSF AVP between schizophrenia patients and HC (13). However, Goldman et al. (34) found elevated plasma AVP levels

in schizophrenic patients with polydipsia. Neuroleptic drugs normalised psychotic symptoms and AVP plasma levels in schizophrenia patients (35,36). In contrast, very recent studies found lower plasma AVP levels in schizophrenia patients than in HC (20,21); higher AVP levels were associated with greater positive symptom severity in female patients (21). Rubins et al. even found lower AVP levels in relatives of schizophrenia patients and therefore suggested AVP levels as a potential marker of biological vulnerability for psychosis (20). Some evidence for a therapeutic potential of AVP in schizophrenia patients was given by Bramilla et al. and Hosseini et al., both of whom found a positive effect of intranasal administration of the AVP analogue desmopressin on (especially negative) symptoms (37,38). Moreover, these results are underlined by results on AVP-deficient Brattleboro rats. These rats have many features of schizophrenia, and these features can be improved by antipsychotic administration (39,40).

Taken together, many studies report about AVP and OT system alterations in schizophrenia and about the therapeutic use of AVT and OT. Because results are still controversial and inconsistent, more investigations are needed to understand the association between alterations in this hormone system and schizophrenia.

Aim of the study

Most studies about alterations in the OT and AVP system in schizophrenia patients are in acute patients, and few studies evaluate the association between clinical characteristics and AVP in schizophrenia and the correlation with OT. Therefore, we investigated whether young men with schizophrenia show alterations in both plasma OT and plasma AVP levels compared with HC and evaluated whether male schizophrenia patients with higher scores for 'autism' PANSS items show lower OT and AVP levels than male schizophrenia patients without such 'autism' symptoms.

Methods

Setting/participants

Forty-one men with a Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) (41) diagnosis of schizophrenia, confirmed by a Structured Clinical Interview for DSM-IV, were enrolled and compared with 45 HC 1–1 matched exactly for sex and age and approximately for intelligence quotient. As we were interested in a 'non-acute' schizophrenia sample with no predominating positive symptoms, the patients were clinically stable and the main inclusion criteria were a maximum PANSS score of 70, a maximum Clinical Global Impressions-Severity (CGI-S) score of 4 (moderately ill) at the

time of enrolment, and age 18–30 years. Thirty-six patients were stabilised on atypical antipsychotics (aripiprazole, clozapine, olanzapine, quetiapine, risperidone, or ziprasidone), and three patients were not taking antipsychotic medication. Patients had to stay on stable pharmacological treatment throughout the examination period (8 days), that is, dose or medication type could not be changed. Exclusion criteria included neurological diseases, head trauma, and substance abuse; drug screening was used to exclude substance abuse. Patients and HC were in a relaxed state at the time of blood sampling, and the room temperature was held at 21°C/70°F.

The study was approved by the ethics committee of the Ludwig Maximilian University, and written informed consent was obtained from all participants before study inclusion.

Laboratory procedures

Blood samples were collected between 08:00 a.m. and 09:00 a.m. on two different days (day 1, day 8); EDTA tubes containing aprotinin 400 IU/ml blood were used to avoid hormone degradation. Samples were kept on ice for up to 1 h until centrifugation at 1500 × g for 15 min at 4°C. Supernatants were collected and stored at –80°C for a maximum of 6 weeks until being assayed.

Plasma OT and AVP were assessed with commercially available ELISA immunoassay kits (Catalogue number: ADI-900-153, Enzo Life Science, Lausen, Germany) according to the method of Taylor et al. and the supplier's instructions. Briefly, to determine OT the samples were diluted fivefold to avoid matrix effects, and the assay was performed on 100 µl. Analyses were performed in triplicates. The intraassay coefficient of variation (CV) was 14.9%, and the interassay CV, determined across 10 separate runs, was 18.95%.

To determine AVP, the samples were diluted twofold, and the assay was performed on 100 µl. The intraassay CV was 5.9%, and the interassay CV, determined across 10 separate runs, was 13.2%.

Assessment instruments

Schizophrenia psychopathology was assessed with the PANSS (2); and disease severity, with the CGI scale (42). PANSS items were divided into positive, negative, and global domains. Moreover, we subdivided by the factor autistic preoccupation according to the factor analyses by White et al. (3). The factor autistic preoccupation is defined by the six PANSS items poor attention (G11), preoccupation (G15), difficulty in abstraction (N5), stereotyped thinking (N7), disturbed volition (G13), and hallucinations (P3). All ratings were performed by the same experienced senior psychiatrist (S.D.) on day 8.

Sociodemographic characteristics were recorded; they included information about childhood, severe life events, number of important attached persons, social network, and partnerships.

Statistical methods

The amount of OT and AVP measured at both collections was investigated for stability and outliers, and the mean level from the two measurements was used in subsequent analyses. This was a warrantable procedure as both OT and AVP levels were consistent across the two measurements: OT levels did not differ significantly between the two measurements in either patients (mean OT1: 254.96 pg/ml, mean OT2: 256.27 pg/ml; $U = 0.641$; $p = 0.521$) or HC (mean OT1: 378.86 pg/ml, mean OT2: 373.06 pg/ml; $U = 0.356$; $p = 0.722$). AVP levels also did not differ significantly between the two measurements in either patients (mean AVP1: 50.62 pg/ml, mean AVP2: 48.07 pg/ml; $U = 0.089$; $p = 0.930$) or HC (mean AVP1: 65.41 pg/ml, mean AVP2: 59.62 pg/ml; $U = 1.406$; $p = 0.160$). OT levels correlated positively between the two measurements in the patient group ($\rho = 0.859$; $p < 0.001^*$) and in the control group ($\rho = 0.963$; $p < 0.001^*$). AVP levels correlated positively between the two measurements in the patient group ($\rho = 0.747$; $p < 0.001^*$) and in the control group ($\rho = 0.857$; $p < 0.001^*$).

Because of the skewed distributions of OT and AVP, the rank-based Wilcoxon–Mann–Whitney test was used to compare patients and HC. With respect to sociodemographic variables χ^2 , Student's t and Wilcoxon–Mann–Whitney tests were applied in accordance with each variable's scale.

The association between OT, AVP, and PANSS items or subscores as well as other clinical and demographic factors in patients was evaluated with Spearman's correlation coefficient. We used the sum of the six PANSS items (poor attention, preoccupation, difficulty in abstraction, stereotyped thinking, disturbed volition, and hallucinations) of the autistic preoccupation factor as the composite score for autistic symptoms (3). Furthermore, we performed a linear regression analysis with OT and AVP as the independent (predictor) variable and PANSS scale scores as the dependent (outcome) variable to identify the set of variables (sociodemographic and related to the PANSS) that best described the levels of OT and AVP in patients.

The predetermined α level was 0.05. In light of the exploratory nature of the study, we did not perform corrections for multiple testing. All analyses were carried out with SPSS software version 17 for statistical analyses and the graphics were generated with the statistical software environment R 2.13.2 (43).

Results

Demographics

The schizophrenia patients and HC did not differ with regard to age (schizophrenia patients: 24.9 ± 3.56 years, range 18–30; HC: 24.6 ± 3.06 years, range 19–30). The patients' mean duration of illness was 6 years (6.2 ± 5.11 years, range 0–20). In the whole group of patients, the PANSS positive score was 10.0 ± 2.68 (range 7–15); the PANSS negative score, 20.1 ± 6.11 (7–30); the PANSS general score, 30.8 ± 6.64 (17–44); and the overall PANSS total score, 61.0 ± 12.06 (34–82). The PANSS autistic preoccupation score was 12.7 ± 4.13 (6–20). Thirteen patients (33%) were being treated with one antipsychotic; 21 (54%), with two antipsychotics; and 2 (5%), with three antipsychotics. Three patients (8%) were not taking antipsychotic medication and data were missing for two patients.

The schizophrenia patients had grown up significantly more often with only one parent or not with their parents ($\chi^2_1 = 4.893$; $p = 0.027^*$) and more often reported a severe life event ($\chi^2_1 = 8.950$; $p = 0.003^*$) compared with HC. The patients reported significantly more often having no former or current partnerships ($\chi^2_1 = 17.628$; $p < 0.001^*$). The schizophrenia group had significantly fewer (3.2 ± 2.19 , range 0–10) important attached persons than the HC (4.9 ± 2.19 , range 2–10; $U = 3.479$; $p < 0.001^*$). Social networking, for example, Facebook, was used less frequently by the schizophrenia patients (68% vs. 93%, $\chi^2_1 = 8.883$; $p = 0.003^*$). Sample characteristics are shown in Table 1.

Oxytocin and arginine-vasopressin

The schizophrenia patients had significantly lower plasma OT levels (median 225.70 pg/ml) than the HC (median 292.60 pg/ml; $U = 2.754$; $p = 0.006$), see Table 2. AVP levels showed a similar trend, with lower levels in the patient group (median 45.48 pg/ml in schizophrenia patients and median 55.36 pg/ml in HC; $U = 1.946$; $p = 0.052$; see Figs 1 and 2 and Table 2). Severe life events ($U = -2.757$; $p = 0.006^*$) and fewer important attached persons ($\rho = -0.278$; $p < 0.010^*$) were associated with lower OT levels. Moreover, lower OT levels correlated with growing up with only one parent or without parents (Kruskal–Wallis Test: $\chi^2_3 = 13.098$; $p < 0.001^*$). Higher OT levels were found in participants who had grown up with both parents. OT plasma levels did not correlate with being in a former or current partnership or with social networking. OT levels did not differ significantly between patients treated with one antipsychotic agent and those treated with more than one antipsychotic agent ($U = 0.016$;

Oxytocin and vasopressin levels in schizophrenia patients

Table 1. Sample characteristics

	Schizophrenia patients (n = 41)	Healthy controls (n = 45)	Test statistic	p-value
Age in years, mean (SD)	24.9 (3.56)	24.6 (3.06)	$t_{94} = 0.322$	0.748
Grown up with				
Both parents [n (%)]	26 (63.4%)	38 (84.4%)	$\chi^2 = 10.888$	0.012*
Only father [n (%)]	2 (4.9%)	0 (0%)		
Only mother [n (%)]	4 (9.8%)	6 (13.3%)		
Not with parents [n (%)]	9 (22.0%)	1 (2.2%)		
History of severe life events [yes, n (%)]	24 (58.5%)	12 (26.7%)	$\chi^2 = 8.953$	
Former partnership [yes, n (%)]	29 (70.7%)	43 (95.6%)	$\chi^2 = 9.700$	0.002*
In current partnership [yes, n (%)]	11 (26.8%)	28 (62.2%)	$\chi^2 = 10.843$	0.001*
No. of important attached persons, [mean (SD)]	3.2 (2.19)	4.9 (2.17)	U = 3.509	< 0.001*
Participates in social networking [n (%)]	28 (68.3%)	43 (95.6%)	$\chi^2 = 11.074$	0.001*
Duration of illness in years [mean (SD)]	6.2 (5.11)	–	–	–
Age at first treatment in years [mean (SD)]	21 (3.69)	–	–	–
PANSS positive score [mean (SD)]	10.0 (2.68)	–	–	–
PANSS negative score [mean (SD)]	20.1 (6.11)	–	–	–
PANSS global score [mean (SD)]	30.8 (6.64)	–	–	–
PANSS total score [mean (SD)]	61.0 (12.06)	–	–	–

PANSS, Positive and Negative Syndrome Scale.

Table 2. OT and AVT levels (pg/ml) in male schizophrenia patients (n = 41) and healthy controls (n = 45). Samples were obtained on two days

Group	Min.	1st Qu.	Median	Mean	3rd Qu.	Max.	IQR
Patient OT	83.89	177.10	225.70	255.60	310.40	575.50	133.32
Control OT	91.34	229.80	292.60	376.00	520.20	1011.00	290.36
Patient AVP	20.38	34.93	45.48	49.35	57.28	112.50	22.36
Control AVP	14.60	41.66	55.36	62.52	77.28	178.20	35.62

1st Qu., 1st quartile; 3rd Qu., 3rd quartile; IQR, interquartile range; Max., maximum; Min., minimum; OT, oxytocin; AVP, arginine-vasopressin.




Fig. 1. Distribution of mean oxytocin levels in schizophrenia patients and healthy controls.




Fig. 2. Distribution of mean arginine vasopressin levels in schizophrenia patients and healthy controls.

$p = 1.000$) and did not correlate with the number of antipsychotics ($\rho = -0.016$; $p = 0.923$).

Within the patient group, we found a negative association between the PANSS negative scale score and OT levels ($\rho = -0.413$; $p = 0.007^*$): Patients with a high PANSS negative scale score had lower plasma OT levels. However, this was not the case for the PANSS positive or general scale score, neither of which correlated with OT levels. The most dominant ‘autistic’ symptoms ‘preoccupation’ (G15; $\rho = -0.537$; $p < 0.001^*$), ‘emotional withdrawal’ (N2, $\rho = -0.531$; $p < 0.001^*$), and ‘passive/apathetic social withdrawal’ (N4, $\rho = -0.509$; $p = 0.001^*$) were

negatively correlated with OT levels (Fig. 3). Regression analysis with OT as the independent (predictor) variable and PANSS negative scale score as the dependent (outcome) variable showed a significant association ($\beta: -0.420$; $t_1 = -2.894$; $p = 0.006^*$). The effects remained significant even after controlling for antipsychotics, age, life events, and important attached persons, none of which was a predicting variable. OT levels did not predict the PANSS positive or general score.

OT levels did not directly correlate with AVP levels in either the patient group ($\rho = 0.082$; $p = 0.614$) or the HC group ($\rho = 0.055$; $p = 0.717$).




Fig. 3. Correlation of Positive and Negative Syndrome Scale (PANSS) items with oxytocin. Several PANSS autistic items correlated with oxytocin levels: emotional withdrawal (N2); passive/apathetic social withdrawal (N4); preoccupation (G15).

AVP levels did not correlate with the PANSS subscale scores or with life events, former or current partnerships, social networking, or the number of important attached persons, and regression analysis revealed no predictive value for clinical symptoms. Schizophrenia patients with former relationships showed higher AVP levels than patients without former relationships ($U = 1.978$; $p = 0.048^*$). AVP levels did not differ significantly between schizophrenia patients treated with one antipsychotic agent and those treated with more than one antipsychotic agent ($U = 1.161$; $p = 0.257$) and did not correlate with the number of antipsychotics ($\rho = 0.157$; $p = 0.346$).

Discussion

The young men with schizophrenia showed lower OT and AVP plasma levels than the HC. As our measurements were taken on two different days and no additional tests were performed on these days, the levels represent the basal hormone state of patients and controls. Patients showed lower social functioning – defined by fewer attached persons, fewer former and current partnerships, and less use of social network – than HC. Moreover, patients had more severe life events and had more often grown up with only one parent or no parents.

Most of the other previous studies focused on OT with regard to the performance of schizophrenia patients in social tests. Kéri et al. (18) found a significant difference in OT levels between their mixed-sex, chronic schizophrenia group and HC only after a trust experiment. However, baseline hormone changes seem particularly relevant with regard to possible new treatment options for schizophrenia. First studies have tested whether adjunctive OT treatment improves schizophrenia symptoms. Positive effects have been

demonstrated for overall symptoms (25–27,29,30), cognition (28), social cognition (30,31), and emotion recognition (33). One study found the greatest effects in a reduction of negative symptoms (27).

Our study found that OT was significantly associated with the PANSS negative symptom score. This finding is in line with the results from Kéri et al. (18), who also found significant associations between low OT levels and PANSS negative symptoms. It is in line also with a previous investigation by Sasayama et al. (16), who found a negative correlation between CSF OT and the negative PANSS subscale in male patients with schizophrenia. Our finding that OT was strongly associated mainly with the ‘autistic’ PANSS items, such as preoccupation, emotional withdrawal, and passive/apathetic social withdrawal, indicates that a subgroup of schizophrenia patients with predominantly negative symptoms may show the most changes in OT metabolism and supports our hypothesis that the ‘autistic’ symptoms of schizophrenia are associated with an alteration in the metabolism of the ‘attachment’ hormone. Moreover, we found an association between lower OT levels and fewer important attached persons and growing up without both parents, which might define social functioning. The hypothesis is underlined by previous findings of blunted plasma OT levels in schizophrenic patients and an association with a low performance in emotional recognition, an autistic symptom (17), although these effects were found only in patients with neuroendocrine dysfunction (polydipsia hyponatremia). Further studies on OT as a potential treatment option in schizophrenia, especially for negative and autistic symptoms, should be performed in this subgroup of patients.

Previous findings on the AVP system and schizophrenia are much more limited. In an earlier study, polydipsic hyponatremic schizophrenia patients showed enhanced AVP and hypothalamic pituitary

adrenal axis responses to stress that appeared attributable to anterior hippocampal dysfunction (17). In contrast, very recent studies demonstrated lower AVP levels in schizophrenia patients than in HC (20,21). Higher AVP levels were associated with greater positive symptom severity in female schizophrenia patients (21). Less is known about the association between negative symptoms and AVP levels, but recent studies demonstrated positive effects on negative symptoms in schizophrenic patients after intranasal administration of an AVP analogue (37,38). In our study, we found no association between AVP levels in schizophrenia patients and symptom severity of positive, negative, or autistic symptoms. However, we found lower AVP plasma levels in male schizophrenia patients than in HC. This finding is in line with results of previous studies (20,21). Therapeutic use of AVP might be discussed for schizophrenia patients – even though we found no direct correlation between AVP levels and clinical symptoms assessed by the PANSS – because recent studies found many features of schizophrenia in AVP-deficient (Brattleboro) rats (39,40) and intranasal administration of an AVP analogue was found to have a positive effect on negative symptoms in schizophrenia patients (37,38). Future studies should focus on measurements of other AVP-related symptoms like aggression, social cognition, and emotion recognition, because these symptoms might not have been appropriately reflected by the PANSS.

Our study may be limited by the fact that we did not ask about sexual activity, which has been reported to affect OT (44). However, we measured the hormones on two different days (days 1 and 8), and the findings showed nearly the same levels and no significant difference. Another limitation is that our results might be gender related and cannot be transferred to female patients. We chose to study men because they show less variation in hormone levels. Most of the patients were on a stable therapeutic dose of one or two antipsychotic agents; the number of antipsychotic agents used for treatment had no effect on the OT plasma level. This is in line with the finding of previous studies that neuroleptic drugs did not affect CSF OT levels in schizophrenic patients (15). However, intake of atypical antipsychotic drugs still might have affected OT and AVP plasma levels. So far, it is unclear whether and how atypical antipsychotic drugs affect the OT and AVP system. For example, studies have found an increase and a decrease in OT levels related to dopaminergic active drugs (45–47). Therefore, results should be confirmed in a drug-free sample to exclude medication effects on hormone levels. Antipsychotics have been found not to stimulate vasopressin release directly, but they may

stimulate it indirectly (36). Moreover, OT plasma levels may not be representative for OT levels in the CSF. Therefore, future studies comparing plasma and CSF levels are required. Last, beside alterations in OT metabolism, many roads could lead to decreased plasma OT levels, including decreased OT synthesis, mRNA expression, translation, and others.

Taken together our results are in line with previous findings of lower OT and AVP levels in schizophrenia patients than in HC and an inverse correlation with symptom severity (16–21). However, some studies did not observe such differences (13,15,16,21) or even demonstrated opposite results (13,14,34). This discrepancy might have different reasons. First, comparability of the different studies is difficult, because cohorts are inhomogeneous with respect to gender (male, female, or mixed gender samples) and method of measurements (plasma or CSF). Moreover, acute psychotic illness might have affected results in some samples, because greater positive symptoms were related to higher plasma OT levels (20) and higher AVP levels (21) in acute schizophrenia patients. Therefore, lower OT and AVP plasma levels might be specifically associated with negative symptoms and autistic symptoms in schizophrenia. If so, OT differences indicate that there might be a disruption in the ability of physiological levels of OT to modulate social cognition in schizophrenic patients. Our results provide further support for an association between social deficits (represented by PANSS autistic symptoms and negative symptoms) and lower OT levels in schizophrenia. Moreover, they support the hypothesis that decreased AVP levels might be a marker of biological vulnerability for psychosis, as previously suggested (20).

We hope that this study will contribute to the future therapeutic potential of OT and AVP in schizophrenia (48). Current treatment options for the negative and autistic symptoms of schizophrenia are very limited and often unsatisfactory for the patient. Therefore, especially the subgroup of schizophrenia patients with these symptoms might eventually profit from new or additional treatment options with hormones.

Acknowledgments

The authors thank Karin Neumeier and Sylvia de Jonge for their contributions to the laboratory work and Jacquie Klesing, Board-certified Editor in the Life Sciences (ELS), for editing assistance with the manuscript. Sandra Dehning and Simone Ruf contributed substantially to the conception and design of the study; to data acquisition, analysis, and interpretation; and to drafting the article. They gave final approval of the version to be published. Tobias Notz contributed

substantially to the acquisition of data and reviewed the article critically as regards important intellectual content. He gave final approval of the version to be published. Kristina Henning-Fast, Dominik Meissner, Anna Buchheim, Brigitta Bondy, and Norbert Müller contributed substantially to the conception and design of the study and reviewed the article critically as regards important intellectual content. They gave final approval of the version to be published. Andrea Jobst, Sebastian Meyer, and Peter Zill contributed substantially to data analysis and interpretation and reviewed the article critically as regards important intellectual content. They gave final approval of the version to be published.

Financial Support

None.

Conflicts of Interest

None.

Ethical Standards

The authors assert that all procedures contributing to this work comply with ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.

References

1. BLEULER E. Dementia Praecox oder Gruppe der Schizophrenien. Handbuch der Psychiatrie. Leipzig: Deuticke ed, 1911.
2. KAY SR, FISZBEIN A, OPLER LA. The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophr Bull* 1987;**13**:261–276. PubMed PMID: 3616518. Epub 1987/01/01. eng.
3. WHITE L, HARVEY PD, OPLER L, LINDENMAYER JP. Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. A multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. The PANSS Study Group. *Psychopathology* 1997;**30**: 263–274. PubMed PMID: 9353855. Epub 1997/01/01. eng.
4. COUTURE SM, PENN DL, ROBERTS DL. The functional significance of social cognition in schizophrenia: a review. *Schizophr Bull* 2006;**32**(Suppl. 1):S44–S63. PubMed PMID: 16916889. Pubmed Central PMCID: PMC2632537. Epub 2006/08/19. eng.
5. TREMEAU F. A review of emotion deficits in schizophrenia. *Dialogues Clin Neurosci* 2006;**8**:59–70. PubMed PMID: 16640115. Pubmed Central PMCID: PMC3181757. Epub 2006/04/28. eng.
6. BRUNE M. 'Theory of mind' in schizophrenia: a review of the literature. *Schizophr Bull* 2005;**31**:21–42. PubMed PMID: 15888423. Epub 2005/05/13. eng.
7. LEIFKER FR, BOWIE CR, HARVEY PD. Determinants of everyday outcomes in schizophrenia: the influences of cognitive impairment, functional capacity, and symptoms. *Schizophr Res* 2009;**115**:82–87. PubMed PMID: 19775869. Epub 2009/09/25. eng.
8. DONALDSON ZR, YOUNG LJ. Oxytocin, vasopressin, and the neurogenetics of sociality. *Science* 2008;**322**:900–904. PubMed PMID: 18988842. Epub 2008/11/08. eng.
9. KOSFELD M, HEINRICHS M, ZAK PJ, FISCHBACHER U, FEHR E. Oxytocin increases trust in humans. *Nature* 2005;**435**: 673–676. PubMed PMID: 15931222. Epub 2005/06/03. eng.
10. DOMES G, HEINRICHS M, MICHEL A, BERGER C, HERPERTZ SC. Oxytocin improves 'mind-reading' in humans. *Biol Psychiatr* 2007;**61**:731–733. PubMed PMID: 17137561. Epub 2006/12/02. eng.
11. DE VRIES GJ. Sex differences in vasopressin and oxytocin innervation of the brain. *Prog Brain Res* 2008;**170**:17–27. PubMed PMID: 18655868. Epub 2008/07/29. eng.
12. LUDWIG M, LENG G. Dendritic peptide release and peptide-dependent behaviours. *Nat Rev Neurosci* 2006;**7**:126–136. PubMed PMID: 16429122. Epub 2006/01/24. eng.
13. BECKMANN H, LANG RE, GATTAZ WF. Vasopressin – oxytocin in cerebrospinal fluid of schizophrenic patients and normal controls. *Psychoneuroendocrinology* 1985;**10**:187–191. PubMed PMID: 4034849. Epub 1985/01/01. eng.
14. LEGROS JJ, GAZZOTTI C, CARVELLI T *et al.* Apomorphine stimulation of vasopressin- and oxytocin-neurophysins. Evidence for increased oxytocinergic and decreased vasopressinergic function in schizophrenics. *Psychoneuroendocrinology* 1992;**17**: 611–617. PubMed PMID: 1287681. Epub 1992/11/01. eng.
15. GLOVINSKY D, KALOGERAS KT, KIRCH DG, SUDDATH R, WYATT RJ. Cerebrospinal fluid oxytocin concentration in schizophrenic patients does not differ from control subjects and is not changed by neuroleptic medication. *Schizophr Res* 1994;**11**:273–276. PubMed PMID: 7910756. Epub 1994/02/01. eng.
16. SASAYAMA D, HATTORI K, TERAISHI T *et al.* Negative correlation between cerebrospinal fluid oxytocin levels and negative symptoms of male patients with schizophrenia. *Schizophr Res* 2012;**139**:201–206. PubMed PMID: 22742979. Epub 2012/06/30. eng.
17. GOLDMAN M, MARLOW-O'CONNOR M, TORRES I, CARTER CS. Diminished plasma oxytocin in schizophrenic patients with neuroendocrine dysfunction and emotional deficits. *Schizophr Res* 2008;**98**:247–255. PubMed PMID: 17961988. Pubmed Central PMCID: 2277481. Epub 2007/10/27. eng.
18. KERI S, KISS I, KELEMEN O. Sharing secrets: oxytocin and trust in schizophrenia. *Soc Neurosci* 2009;**4**:287–293. PubMed PMID: 18671168. Epub 2008/08/02. eng.
19. RUBIN LH, CARTER CS, DROGOS L, POURNAJAFI-NAZARLOO H, SWEENEY JA, MAKI PM. Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. *Schizophr Res* 2010;**124**:13–21. PubMed PMID: 20947304. Pubmed Central PMCID: PMC2981685. Epub 2010/10/16. eng.
20. RUBIN LH, CARTER CS, BISHOP JR *et al.* Reduced levels of vasopressin and reduced behavioral modulation of oxytocin in psychotic disorders. *Schizophr Bull* 2014; 1–11. PubMed PMID: 24619535. Epub 2014/03/13. Eng.
21. RUBIN LH, CARTER CS, BISHOP JR *et al.* Peripheral vasopressin but not oxytocin relates to severity of acute psychosis in women with acutely-ill untreated first-episode psychosis. *Schizophr Res* 2013;**146**:138–143. PubMed PMID: 23465965. Pubmed Central PMCID: PMC3622845. Epub 2013/03/08. eng.
22. CALDWELL HK, STEPHENS SL, YOUNG WS 3RD. Oxytocin as a natural antipsychotic: a study using oxytocin

- knockout mice. *Mol Psychiatry* 2009;**14**:190–196. PubMed PMID: 18227836. Epub 2008/01/30. eng.
23. FEIFEL D, REZA T. Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating. *Psychopharmacology* 1999;**141**:93–98. PubMed PMID: 9952070. Epub 1999/02/10. eng.
 24. LEE PR, BRADY DL, SHAPIRO RA, DORSA DM, KOENIG JI. Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin. *Neuropsychopharmacology* 2005;**30**:1883–1894. PubMed PMID: 15798779. Epub 2005/03/31. eng.
 25. BUJANOW W. Letter: is oxytocin an anti-schizophrenic hormone? *Can Psychiatr Assoc J* 1974;**19**:323 PubMed PMID: 4841051. Epub 1974/06/01. eng.
 26. BAKHAREV VD, TIKHOMIROV SM, LOZHKINA TK. Psychotropic properties of oxytocin. *Probl endokrinol* 1984;**30**:37–41. PubMed PMID: 6718333. Epub 1984/03/01. Psikhotropnye svoistva oksitotsina. rus.
 27. FEIFEL D, MACDONALD K, NGUYEN A *et al.* Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. *Biological Psychiatry* 2010;**68**:678–680. PubMed PMID: 20615494. Epub 2010/07/10. eng.
 28. FEIFEL D, MACDONALD K, COBB P, MINASSIAN A. Adjunctive intranasal oxytocin improves verbal memory in people with schizophrenia. *Schizophr Res* 2012;**139**:207–210. PubMed PMID: 22682705. Epub 2012/06/12. eng.
 29. MODABBERNIA A, REZAEI F, SALEHI B *et al.* Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia: an 8-week, randomized, double-blind, placebo-controlled study. *CNS Drugs* 2013;**27**:57–65. PubMed PMID: 23233269. Epub 2012/12/13. eng.
 30. PEDERSEN CA, GIBSON CM, RAU SW *et al.* Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia. *Schizophr Res* 2011;**132**:50–53. PubMed PMID: 21840177. Epub 2011/08/16. eng.
 31. DAVIS MC, LEE J, HORAN WP *et al.* Effects of single dose intranasal oxytocin on social cognition in schizophrenia. *Schizophr Res* 2013;**147**:393–397. PubMed PMID: 23676253. Epub 2013/05/17. eng.
 32. FISCHER-SHOFTY M, SHAMAY-TSOORY SG, LEVKOVITZ Y. Characterization of the effects of oxytocin on fear recognition in patients with schizophrenia and in healthy controls. *Front Neurosci* 2013;1–9. PubMed PMID: 23882178. Pubmed Central PMCID: PMC3714571. Epub 2013/07/25. eng.
 33. GOLDMAN MB, GOMES AM, CARTER CS, LEE R. Divergent effects of two different doses of intranasal oxytocin on facial affect discrimination in schizophrenic patients with and without polydipsia. *Psychopharmacology* 2011;**216**:101–110. PubMed PMID: 21301811. Epub 2011/02/09. eng.
 34. GOLDMAN MB, ROBERTSON GL, HEDEKER D. Oropharyngeal regulation of water balance in polydipsic schizophrenics. *Clin Endocrinol* 1996;**44**:31–37. PubMed PMID: 8706290. Epub 1996/01/01. eng.
 35. PESKIND ER, RASKIND MA, LEAKE RD, ERVIN MG, ROSS MG, DORSA DM. Clonidine decreases plasma and cerebrospinal fluid arginine vasopressin but not oxytocin in humans. *Neuroendocrinology* 1987;**46**:395–400. PubMed PMID: 3431654. Epub 1987/11/01. eng.
 36. RASKIND MA, COURTNEY N, MURBURG MM *et al.* Antipsychotic drugs and plasma vasopressin in normals and acute schizophrenic patients. *Biol Psychiatry* 1987;**22**:453–462. PubMed PMID: 3567260. Epub 1987/04/01. eng.
 37. BRAMBILLA F, BONDILOTTI GP, MAGGIONI M *et al.* Vasopressin (DDAVP) therapy in chronic schizophrenia: effects on negative symptoms and memory. *Neuropsychobiology* 1989;**20**:113–119. PubMed PMID: 2548116. Epub 1989/01/01. eng.
 38. HOSSEINI SM, FAROKHNIYA M, REZAEI F *et al.* Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial. *Eur Neuropsychopharmacol* 2014; PubMed PMID: 24636461. Epub 2014/03/19. Eng.
 39. FEIFEL D, PRIEBE K. Vasopressin-deficient rats exhibit sensorimotor gating deficits that are reversed by subchronic haloperidol. *Biol Psychiatry* 2001;**50**:425–433. PubMed PMID: 11566159. Epub 2001/09/22. eng.
 40. CILIA J, GARTLON JE, SHILLIAM C, DAWSON LA, MOORE SH, JONES DN. Further neurochemical and behavioural investigation of Brattleboro rats as a putative model of schizophrenia. *J Psychopharmacol (Oxford, England)* 2010;**24**:407–419. PubMed PMID: 19204063. Epub 2009/02/11. eng.
 41. APA. American Psychiatric Association. Washington, DC: Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 1994.
 42. GUY W. ECDEU Assessment Manual for Psychopharmacology — Revised (DHEW Publ No ADM 76-338). Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976, pp. 218–222.
 43. R-Development-Core-Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2011; ISBN 3-900051-07-0, <http://www.R-project.org/>
 44. SALONIA A, NAPPI RE, PONTILLO M *et al.* Menstrual cycle-related changes in plasma oxytocin are relevant to normal sexual function in healthy women. *Horm Behav* 2005;**47**:164–169. PubMed PMID: 15664019. Epub 2005/01/25. eng.
 45. GALFI M, JANAKY T, TOTTH R *et al.* Effects of dopamine and dopamine-active compounds on oxytocin and vasopressin production in rat neurohypophyseal tissue cultures. *Regul Pept* 2001;**98**:49–54. PubMed PMID: 11179778. Epub 2001/02/17. eng.
 46. KISS A, SODERMAN A, BUNDZIKOVA J, PIRNIK Z, MIKKELSEN JD. Zolpidem, a selective GABA(A) receptor alpha1 subunit agonist, induces comparable Fos expression in oxytocinergic neurons of the hypothalamic paraventricular and accessory but not supraoptic nuclei in the rat. *Brain Res Bull* 2006;**71**:200–207. PubMed PMID: 17113947. Epub 2006/11/23. eng.
 47. UVNAS-MOBERG K, ALSTER P, SVENSSON TH. Amperozide and clozapine but not haloperidol or raclopride increase the secretion of oxytocin in rats. *Psychopharmacology* 1992;**109**:473–476. PubMed PMID: 1365865. Epub 1992/01/01. eng.
 48. MACDONALD K, FEIFEL D. Oxytocin in schizophrenia: a review of evidence for its therapeutic effects. *Acta neuropsychiatrica* 2012;**24**:130–146. PubMed PMID: 22736892. Pubmed Central PMCID: PMC3378061. Epub 2012/06/28. Eng.